Orioles to non-tender reliever Jacob Webb; decisions loom ahead of deadline
, a celebration deeply rooted in African heritage and culture, is not only a festival of unity and community but also a culinary journey through a rich tapestry of flavors and traditions. Originating in 1966 during the Civil Rights Movement by activist , Ph.D., Kwanzaa was created as a holiday specifically for African-Americans. The name "Kwanzaa" derives from the Swahili phrase "matunda ya kwanza," meaning "first fruits," harkening back to the times of collective harvest and communal gratitude. Celebrated from December 26 to January 1, each of the seven nights of Kwanzaa is dedicated to a different principle or social value. The sixth night, Kuumba, meaning "creativity," is especially notable for its focus on a festive feast. This feast, or Karamu, is a time for rejoicing in the shared heritage and cultural richness of the African diaspora. While there is no set Kwanzaa menu, it is customary to serve African and African-influenced foods for any Kwanzaa meal. What Food is Eaten on Kwanzaa? The dishes served during Kwanzaa reflect the diverse culinary influences of African, Caribbean, and Southern American cuisines. Some of the traditional and popular dishes include:Ilkay Gundogan insists 'EVERY Man City player has to question themselves' and blames 'mental issues' as Juventus defeat puts Champions League hopes in jeopardy The former club captain was offered a grim assessment after European defeat Man City have now recorded just one win in their last 10 matches played LISTEN NOW to It's All Kicking Off! : Why can't Chelsea win the league? They made seven changes and still scored five. Do you think Liverpool could do that? By TAMARA PRENN Published: 17:59 EST, 11 December 2024 | Updated: 17:59 EST, 11 December 2024 e-mail View comments Ilkay Gundogan has called upon 'every single Manchester City player to question themselves' and fix the team's 'mental issue' after another underconfident performance saw the side fall 2-0 to Juventus in the Champions League . Pep Guardiola 's side were frustrated by the hosts on Wednesday night in a cagey first-half, before Dusan Vlahovic opened the scoring in the 53rd minute. Second-half substitute Weston McKennie doubled the Old Lady's lead at the Allianz Stadium with a superlative acrobatic strike, for which the visitors had no reply. Worryingly for the serial champions, Wednesday's result leaves Man City sitting 22nd in the league standings, well outside the automatic qualification places, and in danger of failing to qualify for the knockout stages all together. In their last 10 games, the English champions have won only once, and in Gundogan's eyes, the team's issue is 'a mental issue'. 'It's very disappointing,' Gundogan told TNT Sports. 'I feel like we had chances to score actually a few goals, but at the moment, it just feels like every attack we concede is so dangerous. I don't know. Ilkay Gundogan did not mince words after Man City's Champions League loss to Juventus The former club captain called upon his team-mates to look within themselves to stamp out 'careless' play Pep Guardiola's side have now recorded only one win in their last 10 matches home and abroad Read More Man City lose a SEVENTH game in 10 to leave Champions League knockout hopes hanging in the balance 'I have a feeling sometimes we are a bit careless on the duels and instead of playing simple, we overcomplicate things. '(Confidence) is a big part of it and obviously that's a mental issue as well. I feel like you can see we are, one action we miss the ball or lose the duel and you see we drop immediately and lose the rhythm. 'They are able to break our rhythm with the smallest of things. In the crucial moments right now we are always doing the wrong things. 'I feel like we know exactly what is going wrong and the reasons, and still if you look at the most part of the games, we don't play bad, (we play) quite good football, we just miss to score and it is not that easy to come back it is so obvious what is going wrong but it is trying to find the switch. This is my personal opinion and how I feel. In a rallying cry to his team-mates, Gundogan added: 'Every single player individually has to question themselves and how they can sacrifice more to contribute.' Man City will now return to England with a view to turning around their lacklustre run against a side with a similarly spotty recent record, crosstown rivals Manchester United. Ilkay Gundogan Champions League Manchester City Share or comment on this article: Ilkay Gundogan insists 'EVERY Man City player has to question themselves' and blames 'mental issues' as Juventus defeat puts Champions League hopes in jeopardy e-mail Add comment
Squid Game season 2, one of the most popular Korean dramas on Netflix, has received appreciation as a sensation by South Korean stars, who were taken aback by the dystopian thriller's global success. The first season garnered international attention, becoming Netflix's most-watched series and topping the charts in 94 countries. ET Year-end Special Reads Corporate Kalesh: Top family disputes of India Inc in 2024 The world of business lost these eminent people in 2024 Fast, faster, fastest: How 2024 put more speed into your shopping Due to its unparalleled success, Squid Game is back again with second season. Following the monumental success of its first season, which captured hearts globally, this season promises to bring even more suspense, action, and emotional depth. Here’s everything you need to know about Squid Game Season 2. Owing to its intriguing teasers and trailers, and a striking starcast with many new additions, the latest season is everything that'll make your holiday season, an exciting one. Actor Lee Jung-Jae, who plays the central role of Seong Gi-Hun aka Player 456 is being joined by a new set of players, each one with their own story. ALSO READ: Squid Game Season 2: When and where to watch the much-awaited Korean thriller's next installment? Check details Squid Game season 2: When and where to watch In case, you haven't watched Squid Game season 2, we have got you covered. Squid Game Season 2 will premiere on Netflix on December 26, 2024. The show will be available for viewers worldwide at 1:31 PM IST in India. Fans can expect all seven episodes to drop at the same time, giving them the chance to binge-watch the entire season. For audiences in India, the show will be available in Hindi, Tamil, and Telugu dubbed versions, making it more accessible to a wider audience. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program When will Squid Game season 2 release in India? While the new season will be releasing almost simultaneously on Netflix across the world, its India premiere time is 1:30 PM. Unlike its first season that had nine episodes of around one hour each, the second season will have seven episodes. Its episode 1 is titled Bread and Lottery. ALSO READ: Amid Sriram Krishnan's criticism on his immigration views, Elon Musk says 'America will lose if...' Both seasons of "Squid Game," as well as its reality competition counterpart, "Squid Game: The Challenge," stream exclusively on Netflix. Plans begin at $6.99 a month, which includes ads. Cost for a Netflix subscription runs as high as $22.99, which is the platform's premium ad-free tier that includes unlimited movies and shows streaming in 4K ultra high-definition. Squid Game season 2: Cast and what to expect? Apart from Lee Jung-Jae, Squid Game 2 will see actors Lee Byung-hun, Wi Ha-jun, and Gong Yoo reprising their roles from Season 1. The new cast includes popular Korean actors like Yim Si-Wan, Kang Ha-Neul, Park Gyu-Young, Lee Jin-Uk, Park Sung-Hoon, Yang Dong-Geun, Kang Ae-Sim, Lee David, Choi Seung-Hyun, Roh Jae-Won, Jo Yu-Ri, and Won Ji. These new actors will bring fresh energy and perspectives to the intense game, with each character's backstory adding new layers to the drama. ALSO READ: 'Did you vote for this Indian to run America?’: Sriram Krishnan, Trump's AI advisor, faces backlash. This happens next In the first season, fans were left on the edge of their seats with a major twist. Seong Gi-hun, the protagonist, chose to stay in South Korea instead of flying to the United States. He made this decision in order to uncover the dark secrets behind the brutal games. Season 2 will pick up from this moment, following Gi-hun’s quest to take down the people responsible for the deadly competition. In the second season of Squid Games, fans can expect conflict between Gi-hun and The Front Man to intensify, as the two characters have very different views on life, the game, and justice. Season 2 will explore their growing rivalry and the moral dilemmas faced by the characters, pushing them to their limits. The game will also become even more dangerous and emotionally charged, with higher stakes than ever before. What about Season 3? Excitingly, Director Hwang Dong-hyuk has confirmed that Squid Game will conclude with a third season. Due to its unparalleled success, the show has already been renewed for a third and final season before the release of the second season. The final chapter is expected to air in 2025. ALSO READ: Yellowstone Season 6 is finally confirmed? Here's why fans think the US series is not ending After the massive success of the first two seasons, the third season will bring the story to its climax. Hwang Dong-hyuk shared his excitement about wrapping up the series, stating, “It’s been almost three years since Season 1, and I am thrilled to bring this story to its conclusion.” The third season will pick up where the second leaves off, delivering a high-stakes showdown and a satisfying resolution for the characters and the mystery behind the game. This conclusion will give fans the closure they have been eagerly waiting for. (You can now subscribe to our Economic Times WhatsApp channel )Govt allocated space for Manmohan Singh's memorial Congress playing 'cheap politics' Nadda
'Money changes everything': Inside the seven-year free fall of Conor McGregor
Shares of Wolfspeed, Inc. ( NYSE:WOLF – Get Free Report ) dropped 3.6% during trading on Thursday . The company traded as low as $7.40 and last traded at $7.47. Approximately 1,162,946 shares changed hands during trading, a decline of 84% from the average daily volume of 7,398,590 shares. The stock had previously closed at $7.75. Analysts Set New Price Targets WOLF has been the subject of several analyst reports. Morgan Stanley raised their price objective on shares of Wolfspeed from $10.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $18.00 price target (down from $20.00) on shares of Wolfspeed in a report on Thursday, November 7th. The Goldman Sachs Group decreased their price objective on Wolfspeed from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Mizuho cut their target price on Wolfspeed from $10.00 to $6.00 and set an “underperform” rating for the company in a research note on Tuesday, November 19th. Finally, Canaccord Genuity Group reduced their target price on Wolfspeed from $25.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $17.21. Get Our Latest Stock Report on Wolfspeed Wolfspeed Trading Down 7.0 % Insider Activity In other Wolfspeed news, Director Darren R. Jackson purchased 36,975 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was acquired at an average cost of $6.76 per share, for a total transaction of $249,951.00. Following the completion of the transaction, the director now directly owns 85,996 shares in the company, valued at approximately $581,332.96. This represents a 75.43 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . Also, Chairman Thomas H. Werner acquired 37,500 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was bought at an average price of $6.53 per share, for a total transaction of $244,875.00. Following the acquisition, the chairman now owns 108,549 shares of the company’s stock, valued at approximately $708,824.97. This trade represents a 52.78 % increase in their position. The disclosure for this purchase can be found here . In the last three months, insiders have bought 78,067 shares of company stock worth $524,747. 0.84% of the stock is currently owned by insiders. Hedge Funds Weigh In On Wolfspeed Institutional investors and hedge funds have recently bought and sold shares of the stock. Arizona State Retirement System boosted its stake in shares of Wolfspeed by 2.3% during the second quarter. Arizona State Retirement System now owns 35,217 shares of the company’s stock valued at $802,000 after purchasing an additional 775 shares during the period. Signaturefd LLC boosted its position in Wolfspeed by 284.3% during the 2nd quarter. Signaturefd LLC now owns 2,087 shares of the company’s stock valued at $48,000 after buying an additional 1,544 shares during the period. Vontobel Holding Ltd. grew its holdings in Wolfspeed by 5.1% in the 3rd quarter. Vontobel Holding Ltd. now owns 37,565 shares of the company’s stock worth $364,000 after acquiring an additional 1,835 shares during the last quarter. New York State Teachers Retirement System increased its position in shares of Wolfspeed by 1.3% in the third quarter. New York State Teachers Retirement System now owns 145,284 shares of the company’s stock valued at $1,409,000 after acquiring an additional 1,885 shares during the period. Finally, ProShare Advisors LLC raised its stake in shares of Wolfspeed by 9.3% during the second quarter. ProShare Advisors LLC now owns 23,395 shares of the company’s stock valued at $532,000 after acquiring an additional 1,993 shares during the last quarter. About Wolfspeed ( Get Free Report ) Wolfspeed, Inc operates as a powerhouse semiconductor company focuses on silicon carbide and gallium nitride (GaN) technologies in Europe, Hong Kong, China, rest of Asia-Pacific, the United States, and internationally. It offers silicon carbide and GaN materials, including silicon carbide bare wafers, epitaxial wafers, and GaN epitaxial layers on silicon carbide wafers to manufacture products for RF, power, and other applications. See Also Receive News & Ratings for Wolfspeed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wolfspeed and related companies with MarketBeat.com's FREE daily email newsletter .Christmas joy spread with Silver Angels
KYIV, Ukraine — NATO and Ukraine will hold emergency talks Tuesday after Russia attacked a central city with an experimental, hypersonic ballistic missile. escalating the nearly 33-month-old war. The conflict is “entering a decisive phase,” Poland’s Prime Minister Donald Tusk said Friday, and “taking on very dramatic dimensions.” Ukraine’s parliament canceled a session as security was tightened following Thursday’s Russian strike on a military facility in the city of Dnipro. In a stark warning to the West, President Vladimir Putin said in a nationally televised speech the attack with the intermediate-range Oreshnik missile was in retaliation for Kyiv’s use of U.S. and British longer-range missiles capable of striking deeper into Russian territory. Russian President Vladimir Putin speaks Friday during a meeting with the leadership of the Russian Ministry of Defense, representatives of the military-industrial complex and developers of missile systems at the Kremlin in Moscow. Putin said Western air defense systems would be powerless to stop the new missile. Ukrainian military officials said the missile that hit Dnipro reached a speed of Mach 11 and carried six nonnuclear warheads, each releasing six submunitions. Speaking Friday to military and weapons industries officials, Putin said Russia will launch production of the Oreshnik. “No one in the world has such weapons,” he said. “Sooner or later, other leading countries will also get them. We are aware that they are under development. “We have this system now,” he added. “And this is important.” Putin said that while it isn’t an intercontinental missile, it’s so powerful that the use of several of them fitted with conventional warheads in one attack could be as devastating as a strike with strategic — or nuclear — weapons. Gen. Sergei Karakayev, head of Russia’s Strategic Missile Forces, said the Oreshnik could reach targets across Europe and be fitted with nuclear or conventional warheads, echoing Putin’s claim that even with conventional warheads, “the massive use of the weapon would be comparable in effect to the use of nuclear weapons.” In this photo taken from a video released Friday, a Russian serviceman operates at an undisclosed location in Ukraine. Kremlin spokesman Dmitry Peskov kept up Russia's bellicose tone on Friday, blaming “the reckless decisions and actions of Western countries” in supplying weapons to Ukraine to strike Russia. "The Russian side has clearly demonstrated its capabilities, and the contours of further retaliatory actions in the event that our concerns were not taken into account have also been quite clearly outlined," he said. Hungarian Prime Minister Viktor Orbán, widely seen as having the warmest relations with the Kremlin in the European Union, echoed Moscow’s talking points, suggesting the use of U.S.-supplied weapons in Ukraine likely requires direct American involvement. “These are rockets that are fired and then guided to a target via an electronic system, which requires the world’s most advanced technology and satellite communications capability,” Orbán said on state radio. “There is a strong assumption ... that these missiles cannot be guided without the assistance of American personnel.” Orbán cautioned against underestimating Russia’s responses, emphasizing that the country’s recent modifications to its nuclear deployment doctrine should not be dismissed as a “bluff.” “It’s not a trick ... there will be consequences,” he said. Czech Republic's Foreign Minister Jan Lipavsky speaks to journalists Friday during a joint news conference with Ukraine's Foreign Minister Andriiy Sybiha in Kyiv, Ukraine. Separately in Kyiv, Czech Foreign Minister Jan Lipavský called Thursday’s missile strike an “escalatory step and an attempt of the Russian dictator to scare the population of Ukraine and to scare the population of Europe.” At a news conference with Ukrainian Foreign Minister Andrii Sybiha, Lipavský also expressed his full support for delivering the necessary additional air defense systems to protect Ukrainian civilians from the “heinous attacks.” He said the Czech Republic will impose no limits on the use of its weapons and equipment given to Ukraine. Three lawmakers from Ukraine's parliament, the Verkhovna Rada, confirmed that Friday's previously scheduled session was called off due to the ongoing threat of Russian missiles targeting government buildings in central Kyiv. In addition, there also was a recommendation to limit the work of all commercial offices and nongovernmental organizations "in that perimeter, and local residents were warned of the increased threat,” said lawmaker Mykyta Poturaiev, who said it's not the first time such a threat has been received. Ukraine’s Main Intelligence Directorate said the Oreshnik missile was fired from the Kapustin Yar 4th Missile Test Range in Russia’s Astrakhan region and flew 15 minutes before striking Dnipro. Test launches of a similar missile were conducted in October 2023 and June 2024, the directorate said. The Pentagon confirmed the missile was a new, experimental type of intermediate-range missile based on its RS-26 Rubezh intercontinental ballistic missile. Thursday's attack struck the Pivdenmash plant that built ICBMs when Ukraine was part of the Soviet Union. The military facility is located about 4 miles southwest of the center of Dnipro, a city of about 1 million that is Ukraine’s fourth-largest and a key hub for military supplies and humanitarian aid, and is home to one of the country’s largest hospitals for treating wounded soldiers from the front before their transfer to Kyiv or abroad. We're all going to die someday. Still, how it happens—and when—can point to a historical moment defined by the scientific advancements and public health programs available at the time to contain disease and prevent accidents. In the early 1900s, America's efforts to improve sanitation, hygiene, and routine vaccinations were still in their infancy. Maternal and infant mortality rates were high, as were contagious diseases that spread between people and animals. Combined with the devastation of two World Wars—and the Spanish Flu pandemic in between—the leading causes of death changed significantly after this period. So, too, did the way we diagnose and control the spread of disease. Starting with reforms as part of Roosevelt's New Deal in the 1930s, massive-scale, federal interventions in the U.S. eventually helped stave off disease transmission. It took comprehensive government programs and the establishment of state and local health agencies to educate the public on preventing disease transmission. Seemingly simple behavioral shifts, such as handwashing, were critical in thwarting the spread of germs, much like discoveries in medicine, such as vaccines, and increased access to deliver them across geographies. Over the course of the 20th century, life expectancy increased by 56% and is estimated to keep increasing slightly, according to an annual summary of vital statistics published by the American Academy of Pediatrics in 2000. Death Records examined data from the Centers for Disease Control and Prevention to see how the leading causes of death in America have evolved over time and to pinpoint how some major mortality trends have dropped off. According to a report published in the journal Annual Review of Public Health in 2000, pneumonia was the leading cause of death in the early 1900s, accounting for nearly 1 in 4 deaths. By the time World War I ended in 1918, during which people and animals were housed together for long periods, a new virus emerged: the Spanish Flu. Originating in a bird before spreading to humans, the virus killed 10 times as many Americans as the war. Many died of secondary pneumonia after the initial infection. Pneumonia deaths eventually plummeted throughout the century, partly prevented by increased flu vaccine uptake rates in high-risk groups, particularly older people. Per the CDC, tuberculosis was a close second leading cause of death, killing 194 of every 10,000 people in 1900, mainly concentrated in dense urban areas where the infection could more easily spread. Eventually, public health interventions led to drastic declines in mortality from the disease, such as public education, reducing crowded housing, quarantining people with active disease, improving hygiene, and using antibiotics. Once the death rates lagged, so did the public health infrastructure built to control the disease, leading to a resurgence in the mid-1980s. Diarrhea was the third leading cause of death in 1900, surging every summer among children before the impacts of the pathogen died out in 1930. Adopting water filtration, better nutrition, and improved refrigeration were all associated with its decline. In the 1940s and 1950s, polio outbreaks killed or paralyzed upward of half a million people worldwide every year. Even at its peak, polio wasn't a leading cause of death, it was a much-feared one, particularly among parents of young children, some of whom kept them from crowded public places and interacting with other children. By 1955, when Jonah Salk discovered the polio vaccine, the U.S. had ended the "golden age of medicine." During this period, the causes of mortality shifted dramatically as scientists worldwide began to collaborate on infectious disease control, surgical techniques, vaccines, and other drugs. From the 1950s onward, once quick-spreading deadly contagions weren't prematurely killing American residents en masse, scientists also began to understand better how to diagnose and treat these diseases. As a result, Americans were living longer lives and instead succumbing to noncommunicable diseases, or NCDs. The risk of chronic diseases increased with age and, in some cases, was exacerbated by unhealthy lifestyles. Cancer and heart disease shot up across the century, increasing 90-fold from 1900 to 1998, according to CDC data. Following the post-Spanish Flu years, heart disease killed more Americans than any other cause, peaking in the 1960s and contributing to 1 in 3 deaths. Cigarette smoking rates peaked at the same time, a major risk factor for heart disease. Obesity rates also rose, creating another risk factor for heart disease and many types of cancers. This coincides with the introduction of ultra-processed foods into diets, which plays a more significant role in larger waistlines than the increasing predominance of sedentary work and lifestyles. In the early 1970s, deaths from heart disease began to fall as more Americans prevented and managed their risk factors, like quitting smoking or taking blood pressure medicine. However, the disease remains the biggest killer of Americans. Cancer remains the second leading cause of death and rates still indicate an upward trajectory over time. Only a few types of cancer are detected early by screening, and some treatments for aggressive cancers like glioblastoma—the most common type of brain cancer—have also stalled, unable to improve prognosis much over time. In recent years, early-onset cancers, those diagnosed before age 50 or sometimes even earlier, have seen a drastic rise among younger Americans. While highly processed foods and sedentary lifestyles may contribute to rising rates, a spike in cancer rates among otherwise healthy young individuals has baffled some medical professionals. This follows the COVID-19 pandemic that began in 2020. At its peak, high transmission rates made the virus the third leading cause of death in America. It's often compared to the Spanish Flu of 1918, though COVID-19 had a far larger global impact, spurring international collaborations among scientists who developed a vaccine in an unprecedented time. Public policy around issues of safety and access also influences causes of death, particularly—and tragically—among young Americans. Gun control measures in the U.S. are far less stringent than in peer nations; compared to other nations, however, the U.S. leads in gun violence. Firearms are the leading cause of death for children and teens (around 2 in 3 are homicides, and 1 in 3 are suicides), and deaths from opioids remain a leading cause of death among younger people. Globally, the leading causes of death mirror differences in social and geographic factors. NCDs are primarily associated with socio-economic status and comprise 7 out of 10 leading causes of death, 85% of those occurring in low- and middle-income countries, according to the World Health Organization. However, one of the best health measures is life expectancy at birth. People in the U.S. have been living longer lives since 2000, except for a slight dip in longevity due to COVID-19. According to the most recent CDC estimates, Americans' life expectancy is 77.5 years on average and is expected to increase slightly in the coming decades. Story editing by Alizah Salario. Additional editing by Kelly Glass. Copy editing by Paris Close. Photo selection by Lacy Kerrick. This story originally appeared on Death Records and was produced and distributed in partnership with Stacker Studio. Get local news delivered to your inbox!
Chennai, Dec 28 (PTI) Amidst severe criticism from various political parties over his whiplash agitation, Tamil Nadu BJP chief K Annamalai on Saturday said his action should be likened to that of a "brother's primal anger" over the sexual assault of his sister. His action should not be viewed as political but ought to be seen as an elder brother's outburst over the "system failure" in the state, Annamalai said a day after he staged a unique whiplash agitation of flogging himself to condemn the ruling DMK and the state police over the handling of the case of sexual assault on a Chennai college student. Also Read | Raigad: Pune School Principal Dharmendra Deshmukh Drowns off Kashid Beach During Picnic Trip in Maharashtra's Murud. "Don't see me as a political party leader but see me as the affected girl's elder brother. It's (inflicting whiplash on himself) like primal anger of a brother because the system has failed," Annamalai told reporters at the airport here when sought for his reaction. "Has the police been impartial in handling the case? No. There was no chance for the FIR to get leaked. How did it get leaked?" the BJP president asked. Also Read | Prayagraj Shocker: 5 Workers Injured in Transmission Tower Collapse in Uttar Pradesh (Watch Video). He lashed himself several times with a whip in front of his house in Coimbatore demanding justice for the Anna University student who was sexually assaulted on Christmas Eve. The police had arrested the suspect in the case. Several political parties including the ruling DMK had mocked Annamalai for the agitation which was also to dislodge the DMK government. He had vowed not to wear sandals till the DMK was dethroned and had even begun a 48-day ritual for a pilgrimage to Murugan temples. Also, he justified his stance on the issue. He said the "system has deteriorated" in the state. Former Governor Dr Tamilisai Soundararajan and BJP members were arrested when they staged a protest demanding justice for the affected girl student. "So I was constrained to take up this agitation. I have taken up the issue with a religious zeal," Annamalai said. (This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)In 2023, the Magnificent Seven stocks—Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta Platforms, and Tesla—proved their worth with substantial gains, dominating market movements. In 2024, their performance has continued to impress, further solidifying their significant influence on the market. Due to their massive market capitalizations, these stocks hold outsized influence on the Nasdaq Composite and S&P 500 indexes, driving broader market trends. Here’s a closer look at each of them: 1. Nvidia (NVDA) - +183.2% YTD Nvidia has been a standout performer in 2024, with a massive 183.2% year-to-date (YTD) gain. The company continues to be the leader in AI and GPU technologies, benefiting from surging demand for AI-powered applications and its dominant position in the AI chip market. Nvidia's Q3 earnings exceeded Wall Street expectations, with a substantial increase in both earnings and revenue compared to last year. However, the stock recently faced a 3% decline amid reports of an investigation in China for anti-monopoly violations. Despite this setback, Nvidia's growth prospects in the AI space remain robust, and it continues to be a key driver of the tech sector.
WASHINGTON — State Rep. Brian Harrison, a Republican, said Friday he plans to meet with top University of Texas System officials after they announced a plan to provide free tuition and waived fees to students whose families make $100,000 or less. While many elected officials have praised the initiative , Harrison criticized it as an “abuse of power” that makes Texas higher education “more socialist than California.” Harrison said Friday he’s unswayed by statements from the system and supporters who say the move will be funded from university endowments, not taxpayers. Harrison compared such statements to someone saying they’re removing water from the shallow side of a pool, not the deep end. It’s all the same water. “Money is fungible, so that doesn’t satisfy me in the slightest,” Harrison said. The new initiative is an expansion of the Promise Plus Program, a needs-based financial aid initiative, and comes amid widespread concerns about the effect of inflation and college costs on families. Gov. Greg Abbott recently prohibited Texas colleges and universities from raising tuition for the next two years. UT System Chancellor James B. Milliken hailed the expansion as a “game changer” that will make “enormous, real difference” to improve college access for all Texans. Not everyone is a fan. Harrison and like-minded House colleagues have compared it to President Joe Biden’s student loan forgiveness plan that drew intense blowback from conservatives and was largely struck down by the courts . They also said such a consequential change in policy should come from the elected lawmakers serving in the Legislature. “There must be consequences,” Harrison said on X . “UT’s budget must be cut, and bureaucrats should be fired.” He led 10 Republican lawmakers, most of them incoming freshmen, in a letter to the regents demanding answers to a litany of questions, including the price tag of the expansion and the source of that money. “What specific statutory authority did the regents rely on to make a decision this consequential, which will have direct financial consequences for our constituents, many of whom are already struggling to put gas in their tanks and food on their tables?” the lawmakers wrote. UT System spokesman Paul Corliss has said the program is not funded through taxes or any kind of public subsidy. “Rather it is funded through existing UT System endowments,” Corliss said. Rep. Donna Howard, a Democrat, hammered that point in a response to Harrison on social media. “There are no tax dollars involved,” Howard said on X . “Higher Ed institutions are already helping families afford college. This expands philanthropic endowments and helps meet affordability goals of (Abbott and the Texas Higher Education Coordinating Board).” Harrison and his colleagues will have to contend with many members of the public embracing a plan that already is encouraging young people to adjust their higher education aspirations. Frank Whitefeather, a high school senior, stayed up until 2:30 a.m. Friday working on his college application essay. He was freshly motivated after the announcement that students whose families make less than $100,000 annually will get free tuition and waived fees at the University of Texas, Austin and other schools in the UT System. “I wouldn’t be in debt,” said Whitefeather, 17. “I wouldn’t have to have student loans.” Whitefeather, who attends Dallas ISD’s Sunset High School, thinks the UT news also could change many of his peers’ lives. It’s already changing his plans. Whitefeather hopes to study engineering and be his own boss one day. Texas A&M and UT Austin were his top two choices, but the free tuition announcement has pushed UT ahead. Harrison said the university system is being contradictory by simultaneously saying it has enough money to offer tuition-free education, but also that a tuition freeze could leave it cash strapped and require more funding from the Legislature. “I guarantee you they’re going to be requesting more tax money from the Legislature next session,” he said. ©2024 The Dallas Morning News. Visit dallasnews.com . Distributed by Tribune Content Agency, LLC.Trump asks Supreme Court to delay TikTok ban so he can weigh in after he takes office
After closing the books on a banner year for U.S. stocks, investors expect to ride seasonal momentum into mid-January when a slew of economic data and a transition of power in Washington could send markets moving. The S&P 500 SPX rose almost 27% in 2024 through Dec. 26, while the technology-heavy Nasdaq Composite index , which surpassed 20,000 for the first time in December, is up 33.4%. November through January is traditionally a strong period in the market, said Michael Rosen, chief investment officer at Angeles Investments. Additionally, stocks tend to do well in the last five trading days of December and into the first two days of January, a phenomenon dubbed the Santa Claus rally, which has driven S&P gains of an average of 1.3% since 1969, according to the Stock Trader’s Almanac. For the last four trading sessions, the S&P rose 2.91%, while the Nasdaq is up 3.3%, lifting hopes for a repeat. “The underlying data suggests that that’s likely to continue,” Rosen said. Just how long that momentum lasts will depend on several forces that could help drive markets in 2025. Monthly U.S. employment data on Jan. 10 should give investors a fresh view into the health and strength of the U.S. economy. Job growth rebounded in November following hurricane- and strike-related setbacks earlier in the year. The market’s strength will be tested again shortly after, when U.S. companies start reporting fourth-quarter earnings. Investors anticipate a 10.6% earnings per share growth in 2025, versus a 12.16% expected rise in 2024, according to LSEG data, although excitement over President-elect Donald Trump’s policies is expected to boost the outlook for some sectors, like banks, energy and crypto. “There’s the hope that taxes and regulations will be lowered or reduced next year, that will help support corporate profits, which are what drive the market in the first place,” said Rosen. Trump’s inauguration on Jan. 20 could also throw the markets some curve balls. He is expected to release at least 25 executive orders in his first day on a range of issues from immigration to energy and crypto policy. Trump has also threatened tariffs on goods from China and levies on products from both Mexico and Canada, as well as to crack down on immigration, creating costs that companies could ultimately pass on to consumers. Helen Given, associate director of trading at Monex USA, said a new administration always brings with it a large degree of uncertainty. There is also a good chance the impact of the Trump administration’s expected trade policies is far from fully priced into global currency markets, she added. “We’re looking ahead to see which of those proposed policies actually are enacted, which might be further down the pipeline,” Given said, adding she expected a big impact on the euro, Mexican peso, the Canadian dollar, and the Chinese yuan. The conclusion of the Federal Reserve’s first monetary policy meeting of the year in late January could also present a challenge to the U.S. stocks rally. Stocks tumbled on Dec. 18 when the Fed implemented its third interest-rate cut for the year and signaled fewer cuts in 2025 because of an uncertain inflation outlook, disappointing investors who had expected lower rates to boost corporate profits and valuations. Still, that could be good for alternative assets like cryptocurrencies. The incoming crypto-friendly Trump administration is adding to a number of catalysts that are boosting crypto investors’ confidence, said Damon Polistina, head of research at investment platform Eaglebrook Advisors. Bitcoin surged above $107,000 this month on hopes of friendlier Trump policies. “Crypto is viewed broadly as a kind of risk on assets. So, any Fed cutting rates is a positive... Any positive economic data in early January will help maintain the momentum that we’re seeing,” Polistina added. Source: ReutersOn brand as ever, Nigel Farage got the news that Reform appears to have surpassed the Tories in membership numbers while attending a traditional Boxing Day hunt. He was filmed for TikTok and Instagram wearing tweeds and a flat-cap, getting the news on his phone. He said: “We’ve done it. We’re through. How about that? We’re now the official opposition.” Sticking out his tongue and smiling straight into the camera, he added: “It’s going to be a long day.” Despite his deliberate efforts to appeal to conservative instincts, Farage’s social media methods are far from traditional for a UK politician. While Keir Starmer and Kemi Badenoch delivered conventional Christmas speeches in suits in front of their festive trees, Farage’s social media offerings were unscripted, casual and broadcast to many more followers. His Christmas day picture featured him in a Santa suit with a baby member of his clan on his knee in what looked very much like an ordinary, suburban family Christmas setting in front of patio doors. These pictures and video clips of Farage are reaching his 5.4m-plus followers in a way that the other party leaders are barely attempting to do, and they are a large part of why Reform appears to be growing so strongly in membership and in the opinion polls. Badenoch posted on X on Thursday to challenge Farage’s claims of surpassing the Tories in membership and to accuse him of faking the projection of the numbers on Conservative party HQ. But her claims that he does not understand the digital age do not add up when you look at the way he has been building support online. While 130,000 members is a drop in the ocean compared with Farage’s social media reach, the overall number of voters, and the kind of mass membership enjoyed by political parties in past decades, those who sign up to become card carriers do matter. They are the foot soldiers who campaign and drop leaflets, set up branch offices, become candidates and eventually form a pool for future leadership talent. The Conservatives claim not to be bothered by Reform’s growing size to rival their own membership base, but their associations are undoubtedly rattled by their increasing share of the vote in council byelections and target for expansion in the local elections next year. Labour should also be worried , after Reform won council byelections in Liverpool and Kent in the last month, as well as surging in Dudley where that allowed the Tories to take a seat off Labour. Sign up to First Edition Our morning email breaks down the key stories of the day, telling you what’s happening and why it matters after newsletter promotion Despite the spat between Badenoch and Farage over which party actually has the highest number of members at this point in time, the fact remains that Reform appears to have the momentum after growing from nothing to a level that rivals an established party. The next battle between them will be over the donors and high-profile defectors – and whether more big money will follow the foot soldiers in switching from the Conservatives to Reform. Past incarnations of Reform – from Ukip to the Brexit party – did not manage to professionalise or attract a broad enough coalition of support to convince donors to make the switch. The test will be if those willing to fund the party increasingly believe Farage is becoming the leader of a viable national entity.
House approves $895B defense bill with military pay raise, ban on transgender care for minors
CM Omar Chairs Meeting To Review Snow Clearance, Restoration Of Power & Water Supply Across J&KCRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $
Teen actor Hudson Meek, who appeared in ‘Baby Driver,’ dies after falling from moving vehicle